SCAND1 Antibody

SCAND1 Antibody: Definition and Target

SCAND1 antibodies are immunoreagents targeting the SCAN Domain Containing 1 protein (UniProt: P57086), encoded by the SCAND1 gene (NCBI Gene ID: 51282). This protein lacks zinc finger motifs but contains a SCAN domain, enabling interactions with transcription factors like MZF1 to modulate gene expression . SCAND1 is involved in reversing epithelial-to-mesenchymal transition (EMT) in cancers, influencing metastasis and proliferation .

Key Features of SCAND1:

• Molecular Weight: ~19 kDa (predicted) .

• Domains: Isolated SCAN domain (60–70 aa) facilitating hetero-oligomerization with SCAN-ZF proteins (e.g., MZF1) .

• Post-Translational Modifications: Phosphorylation sites (S13, S44, T63) and ubiquitination (K144) .

Functional Roles:

• Represses EMT drivers (e.g., ZEB1, TGFBRs) and MAP3K-MEK-ERK signaling in prostate cancer .

• Coordinates with HP1γ and MZF1 to stabilize epithelial phenotypes .

4.1. Mechanistic Studies in Cancer

• EMT Reversal: SCAND1 overexpression in DU-145 prostate cancer cells reduces mesenchymal markers (Vimentin) and relocalizes E-cadherin/β-catenin to cell junctions .

• Proliferation Inhibition: Suppresses ERK-1/2 phosphorylation, linking SCAND1 to MAPK pathway regulation .

4.2. Technical Workflows

• Western Blot: Used at dilutions of 1:500–1:1000 with lysates from human cell lines (e.g., DU-145) .

• Immunofluorescence: Localizes SCAND1 to the nucleus in fixed cells .

Validation and Quality Control

• Epitope Specificity: Antibodies target regions like the C-terminus (AA 150–179) or internal sequences (AA 65–114) .

• Cross-Reactivity: Validated for human, mouse, and rat homologs .

• Structural Validation: Advanced computational tools (e.g., ABodyBuilder2) model antibody-antigen interactions to predict epitope accuracy .

Clinical and Prognostic Relevance

• Cancer Prognosis: High SCAND1/MZF1 expression correlates with better outcomes in pancreatic and head/neck cancers but poorer survival in kidney cancer .

• Therapeutic Potential: Targeting SCAND1-MZF1 interactions may inhibit metastasis in prostate adenocarcinoma .